Skip to main content
. 2022 Jan 5;12:811291. doi: 10.3389/fgene.2021.811291

FIGURE 2.

FIGURE 2

Evaluating the feasibility of detecting ctDNA for early prediction of relapse in CRC patients. (A) Association of cfDNA with levels of ctDNA (<0.01%, 0.01–0.1% and >0.1%) in plasma samples (n = 104) of CRC patients (n = 14). (B) Exemplary illustration of ctDNA dynamics in RAS-mutated CRC patients during adjuvant therapy post-tumor resection. The NGS detection limit is indicated at 0.01% VAF. (C) Comparing the progression free survival (PFS) of CRC patients (n = 14) assessed by conventional imaging-based diagnostics and NGS-based detection of ctDNA. Error bars represent median values and interquartile range.